サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1434989

がん診断におけるAI市場：コンポーネント、がんタイプ、展開、エンドユーザー別- 世界予測2024-2030年

AI in Cancer Diagnostics Market by Component (Hardware, Services, Software), Cancer Type (Brain Tumor, Breast Cancer, Colorectal Cancer), Deployment, End-User - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 195 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
がん診断におけるAI市場：コンポーネント、がんタイプ、展開、エンドユーザー別- 世界予測2024-2030年
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 195 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

がん診断におけるAI市場規模は、2023年に8億9,843万米ドルと推定され、2024年には10億2,778万米ドルに達し、CAGR 13.99%で2030年には22億4,734万米ドルに達すると予測されています。

がん診断におけるAIの世界市場

主な市場の統計
基準年[2023］ 8億9,843万米ドル
予測年 [2024] 10億2,778万米ドル
予測年［2030] 22億4,734万米ドル
CAGR（%） 13.99%
がん診断におけるAI Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスはがん診断におけるAI市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、がん診断におけるAI市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-がん診断におけるAI市場の市場規模および予測は？

2-がん診断におけるAI市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-がん診断におけるAI市場における技術動向と規制の枠組みは？

4-がん診断におけるAI市場における主要ベンダーの市場シェアは？

5-がん診断におけるAI市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 世界人口におけるがんの有病率
      • 世界中のいくつかのがん検診プログラムでの採用が急増
      • 非浸潤がん診断への急激な移行
    • 抑制要因
      • 高コストと訓練を受けた腫瘍専門医の不足
    • 機会
      • がん診断における技術の向上
      • がん診断におけるAIと処理の使用に対する政府の投資
    • 課題
      • サイバー攻撃やデータ侵害に対する脆弱性
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 がん診断におけるAI市場：コンポーネント別

  • ハードウェア
  • サービス
  • ソフトウェア

第7章 がん診断におけるAI市場がんの種類別

  • 脳腫瘍
  • 乳がん
  • 結腸直腸がん
  • 肺がん
  • 前立腺がん

第8章 がん診断におけるAI市場：展開別

  • オンクラウド
  • オンプレミス

第9章 がん診断におけるAI市場：エンドユーザー別

  • がんセンター
  • 病院

第10章 南北アメリカのがん診断におけるAI市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第11章 アジア太平洋地域のがん診断におけるAI市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第12章 欧州・中東・アフリカのがん診断におけるAI市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第13章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析

第14章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • 4baseCare
    • Aidoc
    • Aiosyn
    • Cancer Center.ai
    • ContextVision AB
    • Flatiron Health
    • Freenome Holdings, Inc.
    • Ibex Medical Analytics Ltd.
    • International Business Machines Corporation
    • Kheiron Medical Technologies Limited
    • Lunit Inc.
    • Medial EarlySign
    • Microsoft Corporation
    • Mindpeak GmbH
    • Paige AI, Inc.
    • PathAI, Inc.
    • Proscia Inc.
    • Qritive
    • Quantib B.V.
    • RaySearch Laboratories
    • Siemens Healthineers
    • Tempus Labs, Inc.
    • Therapixel
    • Viz.ai
    • Xavor Corporation
  • 主要な製品ポートフォリオ

第15章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. AI IN CANCER DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. AI IN CANCER DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. AI IN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. AI IN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. AI IN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. AI IN CANCER DIAGNOSTICS MARKET DYNAMICS
  • FIGURE 7. AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2023 VS 2030 (%)
  • FIGURE 8. AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 10. AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2023 VS 2030 (%)
  • FIGURE 12. AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 14. AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. AI IN CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 24. AI IN CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. AI IN CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. AI IN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 6. AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HARDWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. AI IN CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 10. AI IN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN TUMOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. AI IN CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. AI IN CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. AI IN CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 16. AI IN CANCER DIAGNOSTICS MARKET SIZE, BY ON-CLOUD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AI IN CANCER DIAGNOSTICS MARKET SIZE, BY ON-PREMISE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 19. AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AI IN CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM AI IN CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM AI IN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM AI IN CANCER DIAGNOSTICS MARKET SIZE, BY DEPLOYMENT, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM AI IN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. AI IN CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 190. AI IN CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 191. AI IN CANCER DIAGNOSTICS MARKET LICENSE & PRICING
目次
Product Code: MRR-B16853776A9D

[195 Pages Report] The AI in Cancer Diagnostics Market size was estimated at USD 898.43 million in 2023 and expected to reach USD 1,027.78 million in 2024, at a CAGR 13.99% to reach USD 2,247.34 million by 2030.

Global AI in Cancer Diagnostics Market

KEY MARKET STATISTICS
Base Year [2023] USD 898.43 million
Estimated Year [2024] USD 1,027.78 million
Forecast Year [2030] USD 2,247.34 million
CAGR (%) 13.99%
AI in Cancer Diagnostics Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the AI in Cancer Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the AI in Cancer Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the AI in Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include 4baseCare, Aidoc, Aiosyn, Cancer Center.ai, ContextVision AB, Flatiron Health, Freenome Holdings, Inc., Ibex Medical Analytics Ltd., International Business Machines Corporation, Kheiron Medical Technologies Limited, Lunit Inc., Medial EarlySign, Microsoft Corporation, Mindpeak GmbH, Paige AI, Inc., PathAI, Inc., Proscia Inc., Qritive, Quantib B.V., RaySearch Laboratories, Siemens Healthineers, Tempus Labs, Inc., Therapixel, Viz.ai, and Xavor Corporation.

Market Segmentation & Coverage

This research report categorizes the AI in Cancer Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Component
    • Hardware
    • Services
    • Software
  • Cancer Type
    • Brain Tumor
    • Breast Cancer
    • Colorectal Cancer
    • Lung Cancer
    • Prostate Cancer
  • Deployment
    • On-Cloud
    • On-Premise
  • End-User
    • Cancer Centers
    • Hospitals
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the AI in Cancer Diagnostics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the AI in Cancer Diagnostics Market?

3. What are the technology trends and regulatory frameworks in the AI in Cancer Diagnostics Market?

4. What is the market share of the leading vendors in the AI in Cancer Diagnostics Market?

5. Which modes and strategic moves are suitable for entering the AI in Cancer Diagnostics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. AI in Cancer Diagnostics Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of cancer among the global population
      • 5.1.1.2. Proliferating adoption in several cancer screening programs worldwide
      • 5.1.1.3. Exponential shift towards non-invasive cancer diagnosis
    • 5.1.2. Restraints
      • 5.1.2.1. High cost and shortage of trained oncologists
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological improvements in cancer diagnostics
      • 5.1.3.2. Government investments in using AI in cancer diagnostics and treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Vulnerability to cyberattacks and data breaches
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. AI in Cancer Diagnostics Market, by Component

  • 6.1. Introduction
  • 6.2. Hardware
  • 6.3. Services
  • 6.4. Software

7. AI in Cancer Diagnostics Market, by Cancer Type

  • 7.1. Introduction
  • 7.2. Brain Tumor
  • 7.3. Breast Cancer
  • 7.4. Colorectal Cancer
  • 7.5. Lung Cancer
  • 7.6. Prostate Cancer

8. AI in Cancer Diagnostics Market, by Deployment

  • 8.1. Introduction
  • 8.2. On-Cloud
  • 8.3. On-Premise

9. AI in Cancer Diagnostics Market, by End-User

  • 9.1. Introduction
  • 9.2. Cancer Centers
  • 9.3. Hospitals

10. Americas AI in Cancer Diagnostics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific AI in Cancer Diagnostics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa AI in Cancer Diagnostics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. FPNV Positioning Matrix
  • 13.2. Market Share Analysis, By Key Player
  • 13.3. Competitive Scenario Analysis, By Key Player

14. Competitive Portfolio

  • 14.1. Key Company Profiles
    • 14.1.1. 4baseCare
    • 14.1.2. Aidoc
    • 14.1.3. Aiosyn
    • 14.1.4. Cancer Center.ai
    • 14.1.5. ContextVision AB
    • 14.1.6. Flatiron Health
    • 14.1.7. Freenome Holdings, Inc.
    • 14.1.8. Ibex Medical Analytics Ltd.
    • 14.1.9. International Business Machines Corporation
    • 14.1.10. Kheiron Medical Technologies Limited
    • 14.1.11. Lunit Inc.
    • 14.1.12. Medial EarlySign
    • 14.1.13. Microsoft Corporation
    • 14.1.14. Mindpeak GmbH
    • 14.1.15. Paige AI, Inc.
    • 14.1.16. PathAI, Inc.
    • 14.1.17. Proscia Inc.
    • 14.1.18. Qritive
    • 14.1.19. Quantib B.V.
    • 14.1.20. RaySearch Laboratories
    • 14.1.21. Siemens Healthineers
    • 14.1.22. Tempus Labs, Inc.
    • 14.1.23. Therapixel
    • 14.1.24. Viz.ai
    • 14.1.25. Xavor Corporation
  • 14.2. Key Product Portfolio

15. Appendix

  • 15.1. Discussion Guide
  • 15.2. License & Pricing